<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03981861</url>
  </required_header>
  <id_info>
    <org_study_id>16010020</org_study_id>
    <nct_id>NCT03981861</nct_id>
  </id_info>
  <brief_title>Metabolic and Neuro-Endocrine Effect of Treating PCOS in Adolescents</brief_title>
  <official_title>Metabolic and Neuro-Endocrine Effect of Treating PCOS in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Mercy Hospital Kansas City</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To exam in the effect of a combination of low dose Metformin and Spironolactone on functional&#xD;
      brain MRI, menstrual regulation and metabolism in adolescents with PCOS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic Ovarian Syndrome (PCOS) is the most common endocrinopathy in adolescent females&#xD;
      and also one of the most complex. Patients experience an exaggerated ovarian/adrenal androgen&#xD;
      production in response to physiologic and supra-physiologic elevations in insulin. The&#xD;
      hormonal dysregulation is not only associated with acne, hirsutism, and menstrual&#xD;
      irregularity, but also with perpetuated insulin resistance, central adiposity, and clinical&#xD;
      depression.&#xD;
&#xD;
      In the proposed study, we aim to treat a hormonally and metabolically well-defined group of&#xD;
      adolescent girls with PCOS with a combination of two pharmacological agents: metformin&#xD;
      (insulin sensitizer) and spironolactone (anti-androgen) for 6 months. Although&#xD;
      hyperandrogenism is a fundamental component of PCOS and responsible for the perpetuation of&#xD;
      insulin resistance, adiposity and anovulation, there are few pediatric studies that have&#xD;
      examined the benefits of treating both insulin resistance and hyperandrogenism&#xD;
      simultaneously. Preliminary studies in adults, however, suggest synergistic effect of both&#xD;
      spironolactone and metformin (spiro-met) with near normalization of the metabolic and&#xD;
      ovulatory dysfunction. Therefore, we hypothesize that spiro-met will improve adolescent&#xD;
      metabolism, body composition, ovarian morphology/function. We anticipate that our study will&#xD;
      generate key pilot data for further randomized, double blind placebo controlled trials using&#xD;
      both agents.&#xD;
&#xD;
      We also plan to examine functional brain MRI before and after the spiro-met intervention.&#xD;
      This will allow us to inspect the effects of the hyperinsulinemic/androgenic hormonal milieu&#xD;
      in PCOS on structural and functional brain MRI. We hypothesis, that the hormonal environment&#xD;
      in PCOS affects centers of appetite and mood.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2016</start_date>
  <completion_date type="Actual">June 5, 2019</completion_date>
  <primary_completion_date type="Actual">July 9, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oral Glucose Tolerance Test</measure>
    <time_frame>Change Measures: Baseline &amp; 6 Months</time_frame>
    <description>Measurement of glucose and insulin at baseline and 2 hours after 75g of glucola.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Testosterone</measure>
    <time_frame>Change Measures: Baseline &amp; 6 Months</time_frame>
    <description>Total Testosterone measured in ng/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Free Testosterone</measure>
    <time_frame>Change Measures: Baseline &amp; 6 Months</time_frame>
    <description>Free Testosterone measured in ng/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dehydroepiandrosterone Sulfate (DHEAS)</measure>
    <time_frame>Change Measures: Baseline &amp; 6 Months</time_frame>
    <description>DHEAS measured in mcg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>Change Measures: Baseline &amp; 6 Months</time_frame>
    <description>Body Mass Index measured in kg/m2</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>PCOS</condition>
  <arm_group>
    <arm_group_label>Overall Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Metformin and Spironolactone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and Spironolactone</intervention_name>
    <description>Oral Metformin tablet (500 mg/tablet) twice daily for 6 months. Oral Spironolactone tablet (50 mg/tablet) once daily for 6 months.</description>
    <arm_group_label>Overall Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Generally healthy&#xD;
&#xD;
          -  Meeting Androgen Excess Society (AES) diagnostic criteria of PCOS: Menstrual&#xD;
             Dysfunction or PCO ovaries on ultrasound AND clinical or biochemical hyperandrogenism&#xD;
&#xD;
          -  Normal liver and kidney function&#xD;
&#xD;
          -  No chronic illnesses except for stable, treated hypothyroidism&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of metformin and/or spironolactone within the last 6 months&#xD;
&#xD;
          -  Currently on either oral hormonal contraception or other forms of hormonal&#xD;
             contraception such as Depo-Provera, NuvaRing&#xD;
&#xD;
          -  Current or past pregnancy&#xD;
&#xD;
          -  Currently sexually active&#xD;
&#xD;
          -  Psychiatric disorder based on self/parental report&#xD;
&#xD;
          -  Type 2 diabetes (blood glucose &gt; 200mg/dl on OGTT)&#xD;
&#xD;
          -  Anemia (Hct &lt; 35)&#xD;
&#xD;
          -  Impaired kidney function (Baseline creatinine &gt; 1.0 mg)&#xD;
&#xD;
          -  Abnormal liver transaminases &gt; 2 x the upper limit of normal range&#xD;
&#xD;
          -  Potassium elevated outside the reference range (in non-hemolyzed blood sample)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tania Burgert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy Hospital Kansas City</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <results_first_submitted>December 18, 2020</results_first_submitted>
  <results_first_submitted_qc>February 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2021</results_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03981861/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>The pilot study was a non-controlled open label drug intervention study in a sample of adolescent girls attending a polycystic ovary syndrome (PCOS) clinic. Subjects received 6 months combination drug therapy with a combination of low dose metformin and spironolactone.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Treatment with Metformin and Spironolactone&#xD;
Metformin and Spironolactone: Oral Metformin tablet (500 mg/tablet) twice daily for 6 months. Oral Spironolactone tablet (50 mg/tablet) once daily for 6 months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>whole body insulin sensitivity index (WBISI)</title>
          <description>WBISI does not have a lot of normative data to help categorize values. However, &lt; 4.3 is deemed insulin resistant. The lower the number the more insulin resistant.</description>
          <units>μU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.67" spread="4.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.7" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Oral Glucose Tolerance Test</title>
        <description>Measurement of glucose and insulin at baseline and 2 hours after 75g of glucola.</description>
        <time_frame>Change Measures: Baseline &amp; 6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>This was a pilot non-controlled open label drug intervention study in a sample of adolescent girls attending a polycystic ovary syndrome (PCOS) clinic. Subjects received 6 months combination drug therapy with a combination of low dose metformin and spironolactone.</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Glucose Tolerance Test</title>
          <description>Measurement of glucose and insulin at baseline and 2 hours after 75g of glucola.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Testosterone</title>
        <description>Total Testosterone measured in ng/dL</description>
        <time_frame>Change Measures: Baseline &amp; 6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>This was a pilot non-controlled open label drug intervention study in a sample of adolescent girls attending a polycystic ovary syndrome (PCOS) clinic. Subjects received 6 months combination drug therapy with a combination of low dose metformin and spironolactone.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Testosterone</title>
          <description>Total Testosterone measured in ng/dL</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.57" spread="11.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Free Testosterone</title>
        <description>Free Testosterone measured in ng/dL</description>
        <time_frame>Change Measures: Baseline &amp; 6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>This was a pilot non-controlled open label drug intervention study in a sample of adolescent girls attending a polycystic ovary syndrome (PCOS) clinic. Subjects received 6 months combination drug therapy with a combination of low dose metformin and spironolactone.</description>
          </group>
        </group_list>
        <measure>
          <title>Free Testosterone</title>
          <description>Free Testosterone measured in ng/dL</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dehydroepiandrosterone Sulfate (DHEAS)</title>
        <description>DHEAS measured in mcg/dL</description>
        <time_frame>Change Measures: Baseline &amp; 6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>This was a pilot non-controlled open label drug intervention study in a sample of adolescent girls attending a polycystic ovary syndrome (PCOS) clinic. Subjects received 6 months combination drug therapy with a combination of low dose metformin and spironolactone.</description>
          </group>
        </group_list>
        <measure>
          <title>Dehydroepiandrosterone Sulfate (DHEAS)</title>
          <description>DHEAS measured in mcg/dL</description>
          <units>mcg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.89" spread="79.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Body Mass Index (BMI)</title>
        <description>Body Mass Index measured in kg/m2</description>
        <time_frame>Change Measures: Baseline &amp; 6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>This was a pilot non-controlled open label drug intervention study in a sample of adolescent girls attending a polycystic ovary syndrome (PCOS) clinic. Subjects received 6 months combination drug therapy with a combination of low dose metformin and spironolactone.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Body Mass Index measured in kg/m2</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>adverse event data was collected for the duration of the subject's intervention: 6 months</time_frame>
      <desc>Metformin is not known to cause death or hospitalization.</desc>
      <group_list>
        <group group_id="E1">
          <title>Overall Study</title>
          <description>The pilot study was a non-controlled open label drug intervention study in a sample of adolescent girls attending a polycystic ovary syndrome (PCOS) clinic. Subjects received 6 months combination drug therapy with a combination of low dose metformin and spironolactone.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed; Technical problems with measurement leading to unreliable or uninterpretable data. Study was not published for this reason.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Tania Burgert</name_or_title>
      <organization>ChildrensMHC</organization>
      <phone>203 676 4545</phone>
      <email>tsburgert@cmh.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

